GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bausch Health Companies Inc (NYSE:BHC) » Definitions » Financial Strength

BHC (Bausch Health) Financial Strength : 3 (As of Jun. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Bausch Health Financial Strength?

Bausch Health has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Bausch Health Companies Inc displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Bausch Health's Interest Coverage for the quarter that ended in Jun. 2024 was 1.22. Bausch Health's debt to revenue ratio for the quarter that ended in Jun. 2024 was 2.25. As of today, Bausch Health's Altman Z-Score is 0.06.


Competitive Comparison of Bausch Health's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bausch Health's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Financial Strength distribution charts can be found below:

* The bar in red indicates where Bausch Health's Financial Strength falls into.



Bausch Health Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Bausch Health's Interest Expense for the months ended in Jun. 2024 was $-350 Mil. Its Operating Income for the months ended in Jun. 2024 was $426 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $21,208 Mil.

Bausch Health's Interest Coverage for the quarter that ended in Jun. 2024 is

Interest Coverage=-1*Operating Income (Q: Jun. 2024 )/Interest Expense (Q: Jun. 2024 )
=-1*426/-350
=1.22

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Bausch Health Companies Inc interest coverage is 1.22, which is low.

2. Debt to revenue ratio. The lower, the better.

Bausch Health's Debt to Revenue Ratio for the quarter that ended in Jun. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(452 + 21208) / 9612
=2.25

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Bausch Health has a Z-score of 0.06, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 0.06 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bausch Health  (NYSE:BHC) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Bausch Health has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Bausch Health Financial Strength Related Terms

Thank you for viewing the detailed overview of Bausch Health's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Bausch Health Business Description

Traded in Other Exchanges
Address
2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Executives
Seana Carson officer: EVP, General Counsel 400 SOMERSET CORPORATE BLVD, BRIDGEWATER NJ 08807
John S Barresi officer: SVP, Controller & CAO 727 FIFTH AVENUE, NEW YORK NY 10022
Richard Mulligan director C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Tom George Vadaketh officer: EVP, Chief Financial Officer 1727 JOCKEYS WAY, YARDLEY PA 19067
Robert Spurr director, officer: U.S. President-Pharma Business C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon officer: Pres&Co-Head Bausch&Lomb/Int'l C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Frederick Munsch officer: SVP, Controller and CAO C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann officer: EVP AND GENERAL COUNSEL C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Sam Eldessouky officer: EVP & Chief Financial Officer C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Steven D Miller director 16690 COLLINS AVENUE, PH, SUNNY ISLE BEACH FL 33160
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
De Schutter Richard U director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Brett Icahn director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
William D. Humphries officer: EVP, COMPANY GROUP CHAIRMAN C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Valueact Capital Master Fund, L.p. director, other: See remarks ONE LETTERMAN DRIVE, BUILDING D, 4TH FLOOR, SAN FRANCISCO CA 94129